Results 71 to 80 of about 2,710 (195)

Dexamethasone Implant Migration through an Iris Coloboma

Case Reports in Ophthalmology, 2020
Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant, Allergan, Dublin, Ireland), an intravitreal biodegradable implant, is indicated for cystoid macular edema due to various causes.
Yoav Glidai, Shulamit Schwartz, Eyal Cohen   +2 more
doaj   +1 more source

A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®) [PDF]

, 2017
Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion.
Gokhan Demir, Ebru Demet Aygit, Gurkan Erdogan, Irfan Perente, Erdem Eris, Burcin Kepez Yildiz   +5 more
core   +1 more source

Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Uveal melanoma (UM) is the prevailing malignant tumor that develops within the eye in adults, and it has a bleak outlook because of the few treatment choices available and the high likelihood of returning after treatment. Currently, surgical intervention, radiation therapy, and a combination of both modalities are available ...
Alireza Azani, Vahid Ghassemifar, Zahra Mehrdad, Maryam Saberivand, Anahid Bagheripour, Safa Tahmasebi, Hossein Gharedaghi, Malihe Sharafi, Hassan Foroozand, Mohammad Saeed Soleimani Meigoli, Saba Pourali, Arash Salmaninejad, Faeze Ahmadi Beni, Qumars Behfar   +13 more
wiley   +1 more source

Application of Machine Learning to Discriminate Photoreceptor Cell Species in Xenotransplanted Chimeric Retinas

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Photoreceptor transplantation is being studied to restore visual function in retinal diseases causing blindness, including age‐related macular degeneration, hereditary eye diseases, and traumatic retinopathy. Preclinical studies often involve delivering exogenous human photoreceptor cells into animal models' retinas.
Kang V. Li, Annabelle Pan, Ying V. Liu, Bani Antonio‐Aguirre, Joyce Wang, McKaily Adams, Christina McNerney, Sai Bo Bo Tun, Kenneth Jimenez, Yuchen Lu, Zhuolin Li, Minda McNally, Veluchamy A. Barathi, Robert J. Johnston Jr., Mandeep S. Singh   +14 more
wiley   +1 more source

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Magnetically Controllable and Degradable Milliscale Swimmers as Intraocular Drug Implants

Advanced Science, Volume 12, Issue 34, September 11, 2025.
Magnetically controllable degradable milliscale swimmers (MDMS) offer a promising alternative to commercial intraocular drug implants, reducing complications like implant dislocation and uncontrolled drug release. MDMS achieve high velocities in ocular environments, enable real‐time imaging, and deliver drugs effectively without disrupting retinal ...
Erdost Yildiz, Ugur Bozuyuk, Eray Yildiz, Fan Wang, Mertcan Han, Alp Can Karacakol, Devin Sheehan, Yan Yu, Metin Sitti   +8 more
wiley   +1 more source

Changes in Macular Function after Ozurdex for Retinal Vein Occlusion

, 2014
Purpose. To investigate changes in macular function after intravitreal dexamethasone implant (Ozurdex) for macular edema (ME) secondary to retinal vein occlusion (RVO). Methods.
Cavallero E, Borrelli E, Preziosa C, Cascavilla ML, Triolo G, Querques L, Cicinelli MV, Lattanzio R, QUERQUES , GIUSEPPE, BANDELLO , FRANCESCO   +9 more
core   +3 more sources

Subconjunctival dexamethasone implant (Ozurdex) for peripheral ulcerative keratitis. [PDF]

Am J Ophthalmol Case Rep
To report a case of peripheral ulcerative keratitis (PUK) successfully treated with subconjunctival dexamethasone implant (Ozurdex®) injection.An 82-year-old female presented with PUK in the right eye. Systemic immunosuppressive treatment with steroids and methotrexate resulted in complete healing.
Ghoraba HH, Or C, Ahluwalia A, Mekonnen B, Yasar C, Yavari N, Nguyen QD.   +6 more
europepmc   +4 more sources

Intracrystalline Ozurdex®: therapeutic effect maintained for 18 months

Introduction: Ozurdex is a sterile, sustained-release implant of dexamethasone. The device dissolves within the vitreous body and releases dexamethasone. Here we present a clinical case that demonstrates the sustained therapeutic efficacy of Ozurdex when
Duch Samper, Antonio Miguel, Clemente Tomás, Rodrigo, Farías-Rozas, Francisco, Torrecillas-Picazo, Raúl, Osorio Alayo, V., Hernández-Pérez, Delia, Neira-Ibáñez, Paulina   +6 more
core   +1 more source

Association of intravitreal and topical anti‐inflammatory therapies on short‐term anatomical and functional outcomes following epiretinal membrane surgery

Acta Ophthalmologica, Volume 103, Issue 4, Page 416-422, June 2025.
Abstract Purpose Here we examine the association of anti‐inflammatory therapy with anatomical and functional outcomes of epiretinal membrane surgery. Methods The study included consecutive patients having gone through epiretinal membrane surgery at Helsinki University Hospital, Finland, between 2017 and 2021.
Pinja Sutinen, Idan Hecht, Minna Karesvuo, Sohee Jeon, Petteri Karesvuo, Raimo Tuuminen   +5 more
wiley   +1 more source